With the global market for anti-obesity drugs projected to hit $95 billion by 2030, it’s no surprise that compounded semaglutide is gaining traction as a cheaper, more accessible option. But for all its appeal, this route comes with real risks: regulatory uncertainty, legal exposure, and major insurance hurdles.
The post Protecting Your Biotech: Understanding the Risks of Compounded GLP-1s appeared first on MedCity News.
